Recommendations for peritransplantation management of high-risk patients for IFD relapse.^aThe duration of secondary antifungal prophylaxis is individualized; consider stopping after up to 1 year post-HSCT (carefully evaluating for acute and chronic toxicities from antifungals) if patient is in CR, has polymorphonuclear leukocyte (PMN) count >1000 cells per mm³, and no signs or symptoms of active IFD. ^bResume mold-active prophylaxis if GVHD develops (acute or chronic) requiring systemic immunosuppressive therapy. ^cAny triazole antifungal administered with conditioning regimen (eg, busulphan, cyclophosphamide) or calcineurin inhibitors. ^dRole of surveillance with fungal biomarkers in asymptomatic patients receiving mold-active prophylaxis is unproven. MDR, multidrug resistant; TDM, therapeutic drug monitoring.